March 19, 2007 -- AtheroGenics fell 61% on news that AGI-1067 failed to meet its primary endpoint in a Phase III trial for acute coronary syndrome; Acadia Pharma said its anti-psychotic drug candidate was successful in a Phase II trial for schizophrenia; Nymox reported positive data from a long-term test of NX-1207 for benign prostatic hyperplasia; and Alexion received FDA approval to market Soliris for paroxysmal nocturnal hemoglobinuria (PNH). The Centient Biotech 200™ rose 34 points to 3836, an increase of .89%. More details...
